How could Pfizer's investment in the CD228V asset affect Moderna?
Pfizer's strategic ADC investment may increase competitive pressure on Moderna Pfizer entered a co-development and license agreement with Medicus Pharma for the CD228V antibody drug conjugate, providing $2 million for development activities. This asset is focused on treating melanoma, where management believes it could achieve an objective response rate exceeding 30%. As a direct competitor in the biopharmaceutical sector, Pfizer's expansion into advanced ADC technology and precision oncology strengthens its pipeline, potentially intensifying market competition for Moderna.
- Effect
- Mild negative
- How direct
- Brind's reasoning
- When
- Over the long term
- The story
- Still developing
How it reaches Moderna
-
Pfizer made a payment for the CD228V license related to drug development. According to financial reporting, the company recorded a $10 million acquired research and development charge tied to the CD228V asset during the first nine months of 2026.
The full event1independent outlet -
Pfizer is a direct competitor of Moderna in the biopharmaceutical sector. By acquiring rights to CD228V, an ADC targeting melanoma, Pfizer is expanding its focus in precision oncology, which increases the competitive landscape for Moderna.
No report states this step directly. Brind drew it from the reporting on each side of it, so treat it as an informed guess.
-
American biotechnology company
Everything about Moderna
Tap any step to see the evidence behind it.
The facts so far
As reported. Each one links to where it comes from.
- Pfizer entered a co-development and license agreement with Medicus Pharma for CD228V.fool.com
- Pfizer provided $2 million for development activities related to CD228V.fool.com
- CD228V is an antibody drug conjugate (ADC) focused on melanoma.fool.com
- Management believes CD228V could achieve an objective response rate exceeding 30% in melanoma.fool.com
Why it matters
The biopharmaceutical sector is defined by intense competition among major players like Pfizer and Moderna, particularly in high-growth areas such as oncology. Pfizer's strategic move to secure rights to CD228V, an advanced ADC, signals a significant commitment to expanding its precision oncology portfolio.
This focus on targeted therapies, like the CD228V asset, is critical because it allows companies to target specific patient populations with high unmet needs. The success of this new ADC could solidify Pfizer's position as a leader in the oncology market, thereby increasing the competitive pressure on other major players, including Moderna.
What we don't know yet
- How successful will the CD228V asset be in achieving its objective response rate target in melanoma?
- Will Pfizer prioritize the CD228V asset over its existing pipeline programs?
What would change this answer
Who else could feel it
Other possible ripples from the same event.
Reporting
- fool.comYesterday
Keep going
Brind's analysis is written by AI from the reporting linked above and can be wrong. This explainer is a possibility worth considering, not a forecast: steps marked as Brind's reasoning are not stated in the reporting. It is not investment advice; do your own research.